RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) Shares Shorted: Short Interest Down 38.5% in October

RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) was the recipient of a significant decrease in short interest in October. As of October 15th, there was short interest totaling 425 shares, a decrease of 38.5% from the September 30th total of 691 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily volume of 257 shares, the short-interest ratio is presently 1.7 days.

RCN Pareto Strategic Allocation ETF Trading Down 0.1%

PRTO traded down $0.02 during trading on Monday, reaching $26.91. The company had a trading volume of 134 shares. The company has a market capitalization of $17.22 million, a PE ratio of -28.03 and a beta of 1.04. The business’s 50 day moving average is $27.56. RCN Pareto Strategic Allocation ETF has a 52 week low of $24.68 and a 52 week high of $28.58.

Proteon Therapeutics was a biopharmaceutical company focused on developing treatments for patients with kidney and vascular diseases. The company’s research and development efforts centered on therapies designed to address severe and life-threatening conditions, particularly those related to renal disease and vascular access for hemodialysis patients.

One of Proteon Therapeutics’ best-known product candidates was vonapanitase, an investigational enzyme developed to improve vascular access outcomes in patients with end-stage renal disease who require hemodialysis.